Urvi A. Shah - Concepedia

Author

Urvi A. Shah

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Seyboth, P., Shah U, U Shah, U. Shah, U., Shah, U.A. Shah, URVI SHAH, Ubaid Ullah Shah, Uma Shah, Urvi A Shah

374

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Sylvester Comprehensive Cancer Center University of Miami Icahn School of Medicine at Mount Sinai

About

Urvi A. Shah is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	17	632
2	Health Sciences	10	11	412
3	Public Health	2	2	46
4	Cellular Therapies	2	2	121
5	Diabetes	2	2	26

Urvi A. Shah

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial Wendy Atkin, Kate Wooldrage, Donald Maxwell Parkin, The Lancet	2017	369
GPRC5D-Targeted CAR T Cells for Myeloma Sham Mailankody, Sean M. Devlin, Jonathan Landa, New England Journal of Medicine	2022	367
Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study Wendy Atkin, Kate Wooldrage, Amy Brenner, The Lancet Oncology	2017	229
Penicillin-Resistant Streptococcus pneumoniae Strains Recovered in Houston: Identification and Molecular Characterization of Multiple Clones James Versalovic, Vivek Kapur, Edward O. Mason, The Journal of Infectious Diseases Molecular CharacterizationAntimicrobial Resistance GeneAntimicrobial SusceptibilityHealth SciencesAntibiotics	1993	147
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma Ola Landgren, Malin Hultcrantz, Benjamin Diamond, JAMA Oncology	2021	114
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Blood Hematological MalignancyCell TherapyMedicineMalignant Blood DisorderImmunology	2022	97
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies Urvi A. Shah, Elaine Y. Chung, Orsi Giricz, Blood	2018	90
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial Benjamin Diamond, Neha Korde, Alexander M. Lesokhin, The Lancet Haematology Hematological MalignancyOncologyContinuous Lenalidomide MaintenanceHematologyMyeloid Neoplasia	2021	87
Whole-genome landscape of adult T-cell leukemia/lymphoma Yasunori Kogure, Takuro Kameda, Junji Koya, Blood	2021	85
Accelerated single cell seeding in relapsed multiple myeloma Heather Landau, Venkata D. Yellapantula, Benjamin Diamond, Nature Communications	2020	78

Page 1